Understanding the pathophysiology is the key to novel therapies for canine dilated cardiomyopathy

Veterinary Journal

Volumn 162, Issue 3, 2001, Pages 168-169

  Elliott, J ^a   Marr, C M ^a  

^a ROYAL VETERINARY COLLEGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE; ANGIOTENSIN; ATRIAL NATRIURETIC FACTOR; BETA 1 ADRENERGIC RECEPTOR; BETA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; BETA 2 ADRENERGIC RECEPTOR; BETA 2 ADRENERGIC RECEPTOR BLOCKING AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRAIN NATRIURETIC PEPTIDE; CARVEDILOL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENDOTHELIN 1; RENIN;

ANIMAL WELFARE; CLINICAL FEATURE; DISEASE MARKER; DOG DISEASE; DRUG SELECTIVITY; EDITORIAL; HEART DILATATION; HEART FAILURE; NONHUMAN; PATHOPHYSIOLOGY; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SURVIVAL; VETERINARY MEDICINE;

ANIMALIA; CANIS FAMILIARIS;

EID: 0035181551     PISSN: 10900233     EISSN: None     Source Type: Journal    
DOI: 10.1053/tvjl.2001.0615     Document Type: Editorial

References (6)

1. Canine idiopathic dilated cardiomyopathy Part II. Pathophysiology and therapy
2. Adrenomedulin, endothelin, neuropeptide Y, atrial, brain and C-natriuretic prohormone peptides compared as early heart failure indicators
3. Carvedilol
4. Detection of asymptomatic cardiac disease in dogs and cats: Neuroendocrine tests
5. Heart failure and endothelin receptor antagonists
6. Preservation of myocardial beta-adrenergic receptor signalling delays the development of heart failure after myocardial infarction